Bitte wählen Sie:

Universitätsklinikum Essen
Direkteinstieg:
Studien & Forschung

Publications

 

Selected publications

 

Zaremba A, Zimmer L, Griewank KG, Ugurel S, Roesch A, Schadendorf D, Livingstone E.Zaremba A, et al.

Immunotherapy for malignant melanoma.

Internist (Berl). 2020 Jul;61(7):669-675. doi: 10.1007/s00108-020-00812-1.Internist (Berl). 2020. PMID: 32462249 Review. German.

 

Váraljai R, Elouali S, Lueong SS, Wistuba-Hamprecht K, Seremet T, Siveke JT, Becker JC, Sucker A, Paschen A, Horn PA, Neyns B, Weide B, Schadendorf D, Roesch A.Váraljai R, et al.

The predictive and prognostic significance of cell-free DNA concentration in melanoma.

J Eur Acad Dermatol Venereol. 2020 Jun 22. doi: 10.1111/jdv.16766. Online ahead of print.J Eur Acad Dermatol Venereol. 2020. PMID: 32569440 

 

Krahn D, Heilmann G, Vogel FCE, Papadopoulos C, Zweerink S, Kaschani F, Meyer H, Roesch A, Kaiser M.Krahn D, et al.

Zelkovamycin is an OXPHOS Inhibitory Member of the Argyrin Natural Product Family.

Chemistry. 2020 Jul 14;26(39):8524-8531. doi: 10.1002/chem.202001577. Epub 2020 Jun 17.Chemistry. 2020. PMID: 32250484

  

Koch F, Salva KA, Wirtz M, Hadaschik E, Varaljai R, Schadendorf D, Roesch A.Koch F, et al.

Efficacy of cold atmospheric plasma vs. diclofenac 3% gel in patients with actinic keratoses: a prospective, randomized and rater-blinded study (ACTICAP).

 J Eur Acad Dermatol Venereol. 2020 Jun 12. doi: 10.1111/jdv.16735. Online ahead of print.J Eur Acad Dermatol Venereol. 2020. PMID: 32531115

  

Chorti E, Kanaki T, Zimmer L, Hadaschik E, Ugurel S, Gratsias E, Roesch A, Bonella F, Wessendorf TE, Wälscher J, Theegarten D, Schadendorf D, Livingstone E.Chorti E, et al.

Drug-induced sarcoidosis-like reaction in adjuvant immunotherapy: Increased rate and mimicker of metastasis.

Eur J Cancer. 2020 May;131:18-26. doi: 10.1016/j.ejca.2020.02.024. Epub 2020 Apr 2.Eur J Cancer. 2020. PMID: 32248071

 

Metzenmacher M, Váraljai R, Hegedüs B, Cima I, Forster J, Schramm A, Scheffler B, Horn PA, Klein CA, Szarvas T, Reis H, Bielefeld N, Roesch A, Aigner C, Kunzmann V, Wiesweg M, Siveke JT, Schuler M, Lueong SS.Metzenmacher M, et al.

Plasma Next Generation Sequencing and Droplet Digital-qPCR-Based Quantification of Circulating Cell-Free RNA for Noninvasive Early Detection of Cancer

Cancers (Basel). 2020 Feb 4;12(2):353. doi: 10.3390/cancers12020353.Cancers (Basel). 2020. PMID: 32033141

 

Zaremba A, Murali R, Jansen P, Möller I, Sucker A, Paschen A, Zimmer L, Livingstone E, Brinker TJ, Hadaschik E, Franklin C, Roesch A, Ugurel S, Schadendorf D, Griewank KG, Cosgarea I.Zaremba A, et al.

Clinical and genetic analysis of melanomas arising in acral sites.

Eur J Cancer. 2019 Sep;119:66-76. doi: 10.1016/j.ejca.2019.07.008. Epub 2019 Aug 14.Eur J Cancer. 2019. PMID: 31419753

  

Vogel FCE, Bordag N, Zügner E, Trajkovic-Arsic M, Chauvistré H, Shannan B, Váraljai R, Horn S, Magnes C, Thomas Siveke J, Schadendorf D, Roesch A.Vogel FCE, et al.

Targeting the H3K4 Demethylase KDM5B Reprograms the Metabolome and Phenotype of Melanoma Cells.  

J Invest Dermatol. 2019 Dec;139(12):2506-2516.e10. doi: 10.1016/j.jid.2019.06.124. Epub 2019 Jun 21.J Invest Dermatol. 2019. PMID: 31229500

  

Zaremba A, Chorti E, Jockenhöfer F, Bolz S, Sirin S, Glas M, Becker JC, Ugurel S, Roesch A, Schadendorf D, Livingstone E, Hagenacker T, Zimmer L.Zaremba A, et al.

Metastatic Merkel cell carcinoma and myasthenia gravis: contraindication for therapy with immune checkpoint inhibitors?

J Immunother Cancer. 2019 May 29;7(1):141. doi: 10.1186/s40425-019-0626-9.J Immunother Cancer. 2019. PMID: 31142383

  

Shannan B, Matschke J, Chauvistré H, Vogel F, Klein D, Meier F, Westphal D, Bruns J, Rauschenberg R, Utikal J, Forschner A, Berking C, Terheyden P, Dabrowski E, Gutzmer R, Rafei-Shamsabadi D, Meiss F, Heinzerling L, Zimmer L, Livingstone E, Váraljai R, Hoewner A, Horn S, Klode J, Stuschke M, Scheffler B, Marchetto A, Sannino G, Grünewald TGP, Schadendorf D, Jendrossek V, Roesch A.Shannan B, et al.

Sequence-dependent cross-resistance of combined radiotherapy plus BRAFV600E inhibition in melanoma.

Eur J Cancer. 2019 Mar;109:137-153. doi: 10.1016/j.ejca.2018.12.024. Epub 2019 Feb 2.Eur J Cancer. 2019. PMID: 30721788

 

Renáta Váraljai; Kilian Wistuba-Hamprecht; Teofila Seremet; Joey Mark S. Diaz; Jérémie Nsengimana; Antje Sucker; Klaus Griewank; Jan-Malte Placke; Peter A. Horn; Nils von Neuhoff; Batool Shannan; Heike Chauvistré; Felix C. E. Vogel; Susanne Horn; Jürgen C. Becker; Julia Newton-Bishop; Andreas Stang; Bart Neyns; Benjamin Weide; Dirk Schadendorf and Alexander Roesch

Application of Circulating Cell-Free Tumor DNA Profiles for Therapeutic Monitoring and Outcome Prediction in Genetically Heterogeneous Metastatic Melanoma

DOI: 10.1200/PO.18.00229 JCO Precision Oncology - published online February 15, 2019

 

Schadendorf D, van Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S.Schadendorf D, et al.

Melanoma.

Lancet. 2018 Sep 15;392(10151):971-984. doi: 10.1016/S0140-6736(18)31559-9.Lancet. 2018. PMID: 30238891 Review

 

Shannan B, Matschke J, Chauvistré H, Vogel F, Klein D, Meier F, Westphal D, Bruns J, Rauschenberg R, Utikal J, Forschner A, Berking C, Terheyden P, Dabrowski E, Gutzmer R, Rafei-Shamsabadi D, Meiss F, Heinzerling L, Zimmer L, Varaljai R, Hoewner A, Horn S, Klode J, Stuschke M, Scheffler B, Schadendorf D, Jendrossek V, Roesch A.

Sequence-dependent crossresistanceof combined radiotherapy plus BRAFV600E-inhibition in melanoma.

Submitted

 

Vogel F, Bordag N, Zügner E3, Trajkovic-Arsic M, Chauvistré H, Shannan B, Horn S, Váraljai R, Magnes C, Siveke J, Schadendorf D, Roesch A.

Targeting the H3K4 demethylase KDM5B/JARID1B affects the metabolic landscape and malignant phenotype of melanoma cells.

submitted

 

Chauvistré H, Daignault SM, Shannan B, Picard D, Krepler C, Ju RJ, Vogel F, Kaschani F, Ninck S, Sechi A, Keminer O, Varaljai R, Stehbens SJ, Löffek S, Liu Q, Yin X, Jeyakumar K, Gul S, Rahmann S, Horn S, Ehrmann M, Paschen A, Helfrich I, Remke M, Rauh D, Kaiser M, Haass NK, Herlyn M, Schadendorf D, Roesch A.

Overcoming tumor plasticity by chemically enforced phenotype homogenization as a new therapeutic strategy in melanoma.

submitted

 

Váraljai R, Wistuba-Hamprecht K, Seremet T, Diaz JMS, Nsengimana J, Sucker A, Placke JM, Horn PA, Neuhoff N, Shannan B, Chauvistré H, Vogel F, Horn S, Becker JC, Newton-Bishop J, Stang A, Neyns B, Weide B, Schadendorf D, Roesch A.

Application of circulating cell-free tumor DNA profiles to therapeutic monitoring and outcome prediction in genetically heterogeneous metastatic melanoma.

submitted

 

Schadendorf D, Akkooi ACJ, Berking C, Griewank KG, Gutzmer R, Hauschild A, Stang A, Roesch A, Ugurel S.

Lancet Seminar – Melanoma.

The Lancet, accepted for publication

 

Kunz M, Löffler-Wirth H, Dannemann M, Willscher E, Doose G, Kelso J, Kottek T, Nickel B, Hopp L, Landsberg J, Hoffmann S, Tüting T, Zigrino P, Mauch C, Utikal J, Ziemer M, Schulze HJ, Hölzel M, Roesch A, Kneitz S, Meierjohann S, Bosserhoff A, Binder H, Schartl M.

RNA-seq analysis identifies different transcriptomic types and developmental trajectories of primary melanomas.

Oncogene. 2018 Jul 11. doi: 10.1038/s41388-018-0385-y. [Epub ahead of print]

 

Cosgarea I, Ugurel S, Sucker A, Livingstone E, Zimmer L, Ziemer M, Utikal J, Morh P, Pfeiffer C, Pföhler C, Hillen U, Horn S, Schadendorf D, Griewank KG, Roesch A.

Targeted next generation sequencing of mucosal melanomas identifies frequent NF1 and RAS mutations.

Oncotarget. 2017 Jun 20;8(25):40683-40692

 

Krepler C, Sproesser K, Brafford P, Beqiri M, Garman B, Xiao M, Shannan B, Watters A, Perego M, Zhang G, Vultur A, Yin X, Liu Q, Anastopoulos IN, Wubbenhorst B, Wilson MA, Xu W, Karakousis G, Feldman M, Xu X, Amaravadi R, Gangadhar TC, Elder DE, Haydu LE, Wargo JA, Davies MA, Lu Y, Mills GB, Frederick DT, Barzily-Rokni M, Flaherty KT, Hoon DS, Guarino M, Bennett JJ, Ryan RW, Petrelli NJ, Shields CL, Terai M, Sato T, Aplin AE, Roesch A, Darr D, Angus S, Kumar R, Halilovic E, Caponigro G, Jeay S, Wuerthner J, Walter A, Ocker M, Boxer MB, Schuchter L, Nathanson KL, Herlyn M.

A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma.

Cell Rep. 2017 Nov 14;21(7):1953-1967

 

Behera R, Kaur A, Webster MR, Kim S, Ndoye A, Kugel CH, Alicea GM, Wang JX, Ghosh K, Cheng PF, Lisanti S, Marchbank K, Dang V, Levesque MP, Dummer R, Xu X, Heryn M, Aplin AE, Roesch A, Caino MC, Altieri DC, Weeraratna AT.

Inhibition of Age-Related Therapy Resistance in Melanoma by Rosiglitazone-Mediated Induction of Klotho.

Clin Cancer Res. 2017 Feb 23.

 

Roesch A, Paschen A, Landsberg J, Helfrich I, Becker JC, Schadendorf D.

Phenotypic tumour cell plasticity as a resistance mechanism and therapeutic target in melanoma.

Eur J Cancer. 2016 May;59:109-12.

 

Facompre ND, Harmeyer KM, Sole X, Kabraji S, Belden Z, Sahu V, Whelan K, Tanaka K, Weinstein GS, Montone KT, Roesch A, Gimotty PA, Herlyn M, Rustgi AK, Nakagawa H, Ramaswamy S, Basu D.

JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers.

Cancer Res. 2016 Sep 15;76(18):5538-49.

 

Zhao F, Sucker A, Horn S, Heeke C, Bielefeld N, Schrörs B, Bicker A, Lindemann M, Roesch A, Gaudernack G, Stiller M, Becker JC, Lennerz V, Wölfel T, Schadendorf D, Griewank K, Paschen A.

Melanoma lesions independantly acquire T-cell resistance during metastatic latency.

Cancer Res. 2016 Aug 1;76(15):4347-58.

 

Roesch A.

Tumor heterogeneity and plasticity as elusive drivers for resistance to MAPK pathway inhibition in melanoma.

Oncogene. 2015 Jun 4;34(23):2951-7.

 

Schadendorf D, Fisher DE, Garbe C, Gershenwald JE, Grob JJ, Halpern A, Herlyn M, Marchetti MA, McArthur G, Ribas A, Roesch A, Hauschild A.

Melanoma.

Nat Rev Dis Primers. 2015 Apr 23;1:15003

 

Cierlitza M, Chauvistré H, Bogeski I, Hauschild A, Herlyn M, Vogt T, Schadendorf D, Roesch A.

Mitochondrial oxidative stress as a novel therapeutic target to overcome intrinsic drug resistance in melanoma cell subpopulations.

Exp Dermatol. 2015 Feb;24(2):155-7

 

Stoffels I, Morscher S, Helfrich I, Hillen U, Leyh J, Burton NC, Sardella TC, Claussen J, Poeppel TD, Bachmann HS, Roesch A, Griewank K, Schadendorf D, Gunzer M, Klode J.

Metastatic status of sentinel lymph nodes in melanoma determined noninvasively with multispectral optoacoustic imaging.

Sci Transl Med. 2015 Dec 9;7(317):317ra199.

 

Stanisz S, Saul S, Hoth M, Vogt T, Roesch A, Bogeski I.

Orai1 calcium channels regulate melanoma growth and invasion.

Pigment Cell Melanoma Res. 2014 May;27(3):442-53.

 

Stanisz H, Saul S, Müller CS, Kappl R, Niemeyer BA, Vogt T, Hoth M, Roesch A, Bogeski I.

Inverse regulation of melanoma growth and migration by Orai1/STIM2-dependent calcium entry.

Pigment Cell Melanoma Res. 2014 May;27(3):442-53.

 

Roesch A, Vultur A, Bogeski I, Wang H, Zimmermann KM, Speicher D, Körbel C, Laschke MW, Gimotty PA, Philipp SE, Krause E, Pätzold S, Villanueva J, Krepler C, Fukunaga-Kalabis M, Hoth M, Bastian BC, Vogt T, Herlyn M.

Overcoming intrinsic multidrug resistance in melanoma by blocking the mitochondrial respiratory chain of slow-cycling JARID1Bhigh cells.

Cancer Cell. 2013 Jun 10;23(6):811-25.

 

Niessner H, Forschner A, Klumpp B, Honegger JB, Witte M, Bornemann A, Dummer R, Adam A, Bauer J, Tabatabai G, Flaherty K, Sinnberg T, Beck D, Leiter U, Mauch C, Roesch A, Weide B, Eigentler T, Schadendorf D, Garbe C, Kulms D, Quintanilla-Martinez L, and Meier F.

Targeting hyperactivation of the AKT survival pathway to overcome therapy resistance of melanoma brain metastases.

Cancer Med. 2013 Feb;2(1):76-85.

 

Magnitsky S, Roesch A, Herlyn M, Glickson JD. (2011)

In vivo and ex vivo MR Imaging of slowly cycling melanoma cells.

Magn Reson Med. 2011 Nov;66(5):1362-73.

 

Roesch A, Fukunaga-Kalabis M, Schmidt EC, Zabierowski SE, Brafford PA, Gimotty P, Vogt T, Herlyn M.

The dynamic expression of JARID1B in a subpopulation of melanoma is required for continuous tumor growth.

Cell. 2010 May 14;141(4):583-94.

 

Fukunaga-Kalabis M, Martinez G, Nguyen TK, Kim D, Santiago-Walker A, Roesch A, Herlyn M.

Tenascin-C promotes melanoma progression by maintaining the ABCB5-positive side population.

Oncogene. 2010 Nov 18;29(46):6115-24.

 

Roesch A, Mueller AM, Stempfl T, Moehle C, Landthaler M, Vogt T.

RBP2-H1/JARID1B is a transcriptional regulator with a tumor suppressive potential in melanoma cells.

Int J Cancer. 2008 Mar 1;122(5):1047-57.

 

Roesch A, Becker B, Schneider-Brachert W, Landthaler M, Vogt T.

Re-expression of the retinoblastoma-binding protein 2-homolog 1 reveals tumor suppressive functions in highly metastatic melanoma cells.

J Invest Dermatol. 2006 Aug;126(8):1850-9.

 

Roesch A, Becker B, Meyer S, Hafner C, Wild PJ, Landthaler M, Vogt T.

Retinoblastoma Binding Protein 2-Homolog 1: A retinoblastoma binding protein downregulated in malignant melanomas.

Mod Pathol. 2005 Sep;18(9):1249-57.

 

Roesch A, Becker B, Meyer S, Hafner C, Wild PJ, Landthaler M, Vogt T.

Overexpression and hyperphosphorylation of retinoblastoma protein in the progression of malignant melanoma.

Mod Pathol. 2005 Apr;18(4):565-72.

Prof. Dr. med. Alexander Rösch

Prof. Dr. med. Alexander Rösch

Group Leader

E-Mail schreiben Zum Steckbrief